Association between potentially inappropriate medications prescription and health-related quality of life among US older adults

Background: Potentially inappropriate medications (PIMs) are associated with worse health outcomes among older adults. Our objective was to examine the association between PIM prescription and health-related quality of life (HRQoL) among older adults in the United States using nationally representative data. Methods: This was a retrospective study utilizing 2011–2015 Medical Expenditure Panel Survey (MEPS) data. Community dwelling US adults aged 65 years or older were included. A qualified definition operationalized from the 2019 American Geriatrics Society Beers Criteria® was used to define exposure to PIMs during the study period. The Physical Component Summary (PCS) and Mental Component Summary (MCS) of the Medical Outcomes Study 12-Item Short Form Health Survey (SF-12) were used to measure HRQoL. Survey-weighted linear regression models were constructed to investigate the association between PIM exposure and participants' PCS and MCS scores. Analyses were stratified across three age cohorts (65–74, 75–85, and ≥85 years). Results: Unadjusted analysis showed poorer scores in the PIM exposed group for both PCS and MCS (all p < 0.001). PIM exposure was associated with poorer PCS scores across all age groups with those aged 65–74 years (adjusted regression coefficient = −1.60 [95% CI = −2.27, −0.93; p < 0.001]), those 75–84 years (adjusted regression coefficient: −1.49 [95% CI = −2.45, −0.53; p = 0.003]), and those 85 years and older (adjusted regression coefficient = −1.65 [95% CI = −3.03, −0.27; p = 0.02]). PIM exposure was also associated with poorer MCS scores in participants aged 65–74 years (adjusted regression coefficient = −0.69 [95% CI = −1.16, −0.22; p = 0.004]) and 85 years and older (adjusted regression coefficient = −2.01 [95% CI = −3.25, −0.78; p = 0.002]). Conclusions: Our results suggest that patients' exposure to PIMs is associated with poorer HRQoL. Further work is needed to assess whether interventions to deprescribe PIMs may help to improve patients' HRQoL.